Literature DB >> 26652602

Metabolic and coagulation effects of citrate: down to the last detail!

Patrick M Honore1, Rita Jacobs2, Inne Hendrickx2, Elisabeth De Waele2, Viola Van Gorp2, Herbert D Spapen2.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26652602      PMCID: PMC4699326          DOI: 10.1186/s13054-015-1154-8

Source DB:  PubMed          Journal:  Crit Care        ISSN: 1364-8535            Impact factor:   9.097


× No keyword cloud information.
The recently published Liver Citrate Anticoagulation Threshold (L-CAT) trial convincingly showed that continuous renal replacement therapy with regional citrate anticoagulation (CRRT-RCA) was safe and effective in patients with severely impaired liver function. Striking findings were a relatively low incidence of acid–base disorders and a markedly long 72-h filter survival [1]. Nonetheless, we would like to comment on two important metabolic issues. First, the low (2 %) incidence of severe metabolic alkalosis, defined as a pH >7.55, is probably highly underestimated. Indeed, we recently evaluated the occurrence of metabolic alkalosis defined either as a pH >7.50 or as an apparent strong ion difference (SIDa) >45 mmol/L according to the Stewart-Figge methodology [2] in patients undergoing CRRT-RCA with an isonatremic low-chloride containing diluted citrate solution. Calculating SIDa revealed a ninefold increase in the percentage of metabolic alkalosis [3]! Accordingly, applying the SIDa approach likely will uncover a substantially higher incidence of severe metabolic alkalosis in the L-CAT patients. Second, the L-CAT investigators attributed the long filter lifespan to a more automated fine-tuning of citrate and calcium dosing. However, we recently demonstrated that keeping post-filter ionized calcium (iCa) within tight limits (i.e., 0.2–0.3 mmol/L) during CRRT-RCA resulted in a 72-h filter survival comparable with that observed in the L-CAT trial [4]. Post-filter iCa levels in all L-CAT trial groups were within the same range and thus may have accounted for a better preserved filter patency. We agree with Honoré et al. that the use of the Stewart-Figge approach probably would have discovered a higher incidence of alkalosis in the study population of the L-CAT study [1]. However, in clinical practice as well as in other studies investigating RCA the Henderson and Hasselbalch approach is used. For practical reasons in this multicenter trial and to allow better comparisons with other studies, we decided to use the latter approach in the L-CAT study. The major outcome parameter for safety in the L-CAT study was the incidence of severe acidosis (pH ≤7.2) or alkalosis (pH ≥7.5) in patients with different degrees of liver failure. Most important, we found no significant difference between these groups and this was true not only for pH, but also for bicarbonate concentration. Thus, even if the overall incidence of alkalosis might have been slightly different using the Stewart-Figge approach, most probably no differences between the study groups would have been detected this way. Regarding the problem of metabolic alkalosis during RCA, it is of note that other colleagues, i.e., Oudemanns-van Straaten et al. [5], reported a significantly higher incidence of metabolic alkalosis (bicarbonate >30 mmol/L) in patients treated with conventional bicarbonate containing solutions in systemic anticoagulated continuous veno-venous hemofiltration (CVVH; 26 %) compared with those who were treated with RCA-CVVH (9 %). This observation clearly shows an urgent need to analyze different protocols in CRRT with regard to their efficiency to control acid–base state. Of note, we agree that keeping ionized calcium concentrations within the extracorporeal circuit in tight limits is the most important task in terms of avoiding filter clotting in RCA-CRRT. In vitro data showed that iCa has to be lowered to at least <0.4 mmol/L to provide sufficient anticoagulation [6]. Discussing filter lifetime as efficacy endpoint, the L-CAT study showed a filter patency rate of >90 % after 72 hours if treatment stops not caused by clotting were censored. Thus, the filter clotting rate has decreased continuously compared with earlier publications of Morgera et al. [7] and Kalb et al. [8], which used exactly the same RCA protocol. Obviously, with increasing experience and training of staff, clotting events can nowadays be avoided almost completely. This way, safe and effective CRRT can be applied and delivery failure is avoidable.
  8 in total

1.  Citrate anticoagulation for extracorporeal circuits: effects on whole blood coagulation activation and clot formation.

Authors:  A Calatzis; M Toepfer; W Schramm; M Spannagl; H Schiffl
Journal:  Nephron       Date:  2001-10       Impact factor: 2.847

2.  The acid-base effect of changing citrate solution for regional anticoagulation during continuous veno-venous hemofiltration.

Authors:  M Egi; T Naka; R Bellomo; C C Langenberg; W Li; N Fealy; I Baldwin
Journal:  Int J Artif Organs       Date:  2008-03       Impact factor: 1.595

3.  A safe citrate anticoagulation protocol with variable treatment efficacy and excellent control of the acid-base status.

Authors:  Stanislao Morgera; Michael Schneider; Torsten Slowinski; Ortrud Vargas-Hein; Heidrun Zuckermann-Becker; Harm Peters; Detlef Kindgen-Milles; Hans-Hellmut Neumayer
Journal:  Crit Care Med       Date:  2009-06       Impact factor: 7.598

4.  Citrate Formulation Determines Filter Lifespan during Continuous Veno-Venous Hemofiltration: A Prospective Cohort Study.

Authors:  Rita Jacobs; Patrick M Honoré; Sean M Bagshaw; Marc Diltoer; Herbert D Spapen
Journal:  Blood Purif       Date:  2015-08-22       Impact factor: 2.614

5.  Regional citrate anticoagulation for high volume continuous venovenous hemodialysis in surgical patients with high bleeding risk.

Authors:  Robert Kalb; Rainer Kram; Stanislao Morgera; Torsten Slowinski; Detlef Kindgen-Milles
Journal:  Ther Apher Dial       Date:  2012-08-29       Impact factor: 1.762

6.  Citrate anticoagulation for continuous venovenous hemofiltration.

Authors:  Heleen M Oudemans-van Straaten; Rob J Bosman; Matty Koopmans; Peter H J van der Voort; Jos P J Wester; Johan I van der Spoel; Lea M Dijksman; Durk F Zandstra
Journal:  Crit Care Med       Date:  2009-02       Impact factor: 7.598

7.  Some metabolic issues should not be neglected when using citrate for continuous renal replacement therapy!

Authors:  Rita Jacobs; Patrick M Honore; Herbert D Spapen
Journal:  Crit Care       Date:  2015-02-06       Impact factor: 9.097

8.  Safety and efficacy of regional citrate anticoagulation in continuous venovenous hemodialysis in the presence of liver failure: the Liver Citrate Anticoagulation Threshold (L-CAT) observational study.

Authors:  Torsten Slowinski; Stanislao Morgera; Michael Joannidis; Thomas Henneberg; Reto Stocker; Elin Helset; Kirsti Andersson; Markus Wehner; Justyna Kozik-Jaromin; Sarah Brett; Julia Hasslacher; John F Stover; Harm Peters; Hans-H Neumayer; Detlef Kindgen-Milles
Journal:  Crit Care       Date:  2015-09-29       Impact factor: 9.097

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.